RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients

Prostate Cancer and Prostatic Diseases ◽

10.1038/pcan.2013.35 ◽

2013 ◽

Vol 16 (4) ◽

pp. 382-386 ◽

Author(s):

L A Kachnic ◽

S L Pugh ◽

P Tai ◽

M Smith ◽

E Gore ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Cancer Patients ◽

Phase Iii ◽

Phase Iii Trial ◽

Prevention Of Osteoporosis

Download Full-text

582 CARDIOVASCULAR SAFETY OF DEGARELIX: RESULTS FROM A 12-MONTH, COMPARATIVE, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP PHASE III TRIAL IN PROSTATE CANCER PATIENTS

The Journal of Urology ◽

10.1016/j.juro.2010.02.841 ◽

2010 ◽

Vol 183 (4S) ◽

Author(s):

Laurence Klotz ◽

Matthew Smith ◽

Bo-Eric Persson ◽

Tine Kold Olesen ◽

Arthur Wilde

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Iii ◽

Cardiovascular Safety ◽

Phase Iii Trial ◽

Download Full-text

Treatment of bone complications in advanced prostate cancer: Rationale for bisphosphonate use and results of a phase III trial with zoledronic acid

Seminars in Oncology ◽

10.1053/sonc.2002.37418 ◽

2002 ◽

Vol 29 (6 Suppl 21) ◽

pp. 19-27 ◽

Author(s):

Fred Saad

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Advanced Prostate Cancer ◽

Phase Iii ◽

Phase Iii Trial ◽

Bone Complications

Download Full-text

Patients' self-assessment of tolerance and quality of life during docetaxel-based chemotherapy: Results from a phase III trial in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.9123 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 9123-9123 ◽

Author(s):

F. Joly ◽

G. Gravis ◽

S. Oudard ◽

M. Soulie ◽

B. Esterni ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Cancer Patients ◽

Metastatic Prostate Cancer ◽

Phase Iii ◽

Self Assessment ◽

Phase Iii Trial

Download Full-text

Safety results of a phase III trial evaluating ADT+ docetaxel versus ADT alone in hormone-naïve metastatic prostate cancer patients (GETUG-AFU 15/0403).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4681 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4681-4681 ◽

Author(s):

I. Latorzeff ◽

B. Esterni ◽

M. Habibian ◽

G. Delplanque ◽

C. Theodore ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Metastatic Prostate Cancer ◽

Phase Iii ◽

Phase Iii Trial

Download Full-text

Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparative bone turnover marker and safety data

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)80418-0 ◽

2006 ◽

Vol 4 (2) ◽

pp. 164-165

Author(s):

J.-J. Body ◽

Lichinitser ◽

S. Tjulandin ◽

B. Bergström

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Bone Turnover ◽

Bone Metastases ◽

Cancer Patients ◽

Bone Turnover Marker ◽

Safety Data ◽

Phase Iii ◽

Breast Cancer Patients ◽

Phase Iii Trial

Download Full-text

Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial

Annals of Nuclear Medicine ◽

10.1007/s12149-018-1278-4 ◽

2018 ◽

Vol 32 (8) ◽

pp. 553-560 ◽

Author(s):

Michael J. Seider ◽

◽

Stephanie L. Pugh ◽

Corey Langer ◽

Gwen Wyatt ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Phase Iii ◽

Phase Iii Trial ◽

Breast And Prostate Cancer

Download Full-text

TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5007 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5007-5007 ◽

Author(s):

Gillian M. Duchesne ◽

Julie Bassett ◽

Catherine D'Este ◽

Mark Frydenberg ◽

Leo Ledwich ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation Therapy ◽

Androgen Deprivation ◽

Phase Iii ◽

Phase Iii Trial

Download Full-text

How should we treat castration-resistant prostate cancer patients who have received androgen deprivation therapy (ADT) plus docetaxel upfront for hormone-sensitive diseae? Mature analysis of the GETUG-AFU 15 phase III trial

Annals of Oncology ◽

10.1093/annonc/mdw372.45 ◽

2016 ◽

Vol 27 ◽

pp. vi259 ◽

Author(s):

P. Lavaud ◽

G. Gravis ◽

C. Legoupil ◽

S. Foulon ◽

F. Joly ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Androgen Deprivation Therapy ◽

Androgen Deprivation ◽

Phase Iii ◽

Castration Resistant Prostate Cancer ◽

Phase Iii Trial ◽

Castration Resistant ◽

Hormone Sensitive ◽

Mature Analysis

Download Full-text

7016 Degarelix versus leuprolide in prostate cancer patients: new prostate-specific antigen data from a phase III trial (CS21)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71394-1 ◽

2009 ◽

Vol 7 (2) ◽

pp. 411 ◽

Author(s):

B. Tombal ◽

K. Miller ◽

L. Boccon-Gibod ◽

F. Schröder ◽

T.K. Olesen ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Prostate Specific Antigen ◽

Specific Antigen ◽

Phase Iii ◽

Phase Iii Trial

Download Full-text

634P Prognostic value of the modeled PSA kinetic parameter (KELIM) in prostate cancer patients with rising PSA after primary local therapy treated in a prospective phase III trial with ADT +/- docetaxel

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1147 ◽

2021 ◽

Vol 32 ◽

pp. S666

Author(s):

A. Carrot ◽

R-T. Elaidi ◽

O. Colomban ◽

D. Maillet ◽

M. Tod ◽

...

Keyword(s):

Prostate Cancer ◽

Kinetic Parameter ◽

Cancer Patients ◽

Prognostic Value ◽

Local Therapy ◽

Phase Iii ◽

Phase Iii Trial ◽

Prospective Phase

Download Full-text